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Figure 1. Network of different placebo comparisons.
Figure 2. Standardized mean differences of active treatments for pain at
12 weeks comparing results from differential placebo effect network and
Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56S24microarray analysis of unique synovial tissue samples of early OA
patients and of experimental OA, to identify common pathways that
may determine progression of cartilage damage in this disease.
Methods: From a subpopulation of patients (n¼ 25) that entered the
CHECK Cohort study (Cohort Hip and Cohort Knee) and 6 controls,
synovial biopsies from the knee joint were collected at baseline and 2
and 5 years after inclusion. CHECK is a prospective 10-year follow-up
study on participants with early osteoarthritis-related complaints ini-
tiated by the Dutch Arthritis Association. Patients that entered the
cohort suffered from knee and/or hip pain and did not see a general
practitioner because of these complaints, longer than 6 months before
inclusion. At baseline and follow-up, highly standardized radiographs
were taken, and analyzed using the KIDA (Knee Image Digital Analysis)
system. Progression of joint damage was determined based on joint
space width and osteophyte formation. Synovial samples from baseline
were analysed using histology and affymetrix U133-plus-2.0 chips.
Analysis of microarray datawas performed using Partek Genomics Suite
software and functional annotation clustering (FAC) and pathway
analysis was done using DAVID.
Results: Upon histological examination at baseline, we found that lin-
ing thickness and synovitis were enhanced in the CHECK biopsies
compared to control synovia. Gene expression proﬁles of control
synovia were compared to our unique set of CHECK synovia. FAC
analysis indicated enrichment of several biological processes and sig-
naling pathways, including regulation of macrophage differentiation,
innate immune responses, cell migration, TGFb-, BMP- and wnt-sig-
naling. This indicates activation of the synovium in the CHECK patients
compared to controls. Next we compared synovial tissue taken at
baseline of CHECK-patients with radiological damage (KL1) with
CHECK-patients without joint damage (KL¼0) at baseline. Among the
genes that were strongest associated with cartilage damagewere MMP-
1 (18-fold), MMP-3 (10-fold), and S100A8 (6-fold). Immunohis-
tochemical staining revealed that expression of MMP-1 andMMP-3was
highest in the synovial lining layer. FAC analysis showed that chemo-
taxis, innate immune response and metalloproteases and pathways like
the complement-activation pathway were signiﬁcantly enriched and
thus associated with joint damage at baseline. To determine whether
any of the regulated genes and pathways were predictive for pro-
gression of joint damage between baseline and t¼5, we identiﬁed 13
patients that weremarked progressors and 8 non-progressors, based on
JSW and osteophyte size at these time points. At baseline, neither
minimum JSW nor osteophyte size differed between the groups.
Approximately 200 genes were expressed more than 2-fold higher in
synovium of progressors, versus non-progressors. Among these genes
were genes from the wnt-signaling pathway: WISP1, Fzd1, Fzd8 and
Fzd10, whereas FrzB was downregulated. Also inﬂammatory factors,
like IL-1, IL-6, S100A9, complement components C4a and CFI, and FN1
were more than 2-fold increased, as was MMP-1. In addition, macro-
phagemarkers like CD14, MHC class II genes, scavenger receptor A3 and
Cxcr2 were positively associated with progression. This indicates that
expression of these factors may predict, or even be involved in, pro-
gression of joint damage in OA patients. Using FAC we identiﬁed
inﬂammatory response, macrophage differentiation, blood vessel for-
mation, ossiﬁcation and cell migration to be enriched in patients that
show progression of damage 5 years later. Histologically, the pro-
gressors showed a higher thickness of the lining layer compared to non-
progressors, 2.0 vs 1.2 respectively on an arbitrary scale. No differences
were found on other parameters like synovitis and villi formation.
Conclusions: All in all, these data suggest an active role for the syno-
vium in OA pathology, and identiﬁes pathways that are likely to be
involved. We identiﬁed genes that are involved in the inﬂammatory
response and may be predictive for progression of OA. From histology
and the expression data, it appears that presence of macrophages,
especially in the lining layer, is associated with progression of joint
damage in OA. In addition, synovial expression of wnt-signaling genes
seems important in progression of damage as well.
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DIFFERENTIAL RESPONSE OF PLACEBO TREATMENTS IN
OSTEOARTHRITIS TRIALS: A SYSTEMATIC REVIEW AND NETWORK
META-ANALYSIS
R.R. Bannuru y, C.H. Schmid z, M.C. Sullivan y, D.M. Kent y, J.B. Wong y,
T.E. McAlindon y. y Tufts Med. Ctr., Boston, MA, USA; zBrown Univ.,
Providence, RI, USAPurpose: Placebo controls are essential when evaluating the effective-
ness of medical treatments. However, systematic variation in the mag-
nitude of response according to the type of placebo deliveredwould have
important implications for the interpretation of placebo-controlled trials,
and our knowledge base on this issue is weak. We aimed to determine
whether different types of placebos employed in knee osteoarthritis (OA)
trials are associatedwith different effect sizes, and to quantify the impact
of this difference on the estimates of treatment effects.
Methods: We searched Medline, EMBASE, Web of Science, and
Cochrane Database from inception to November 2013 with no language
restrictions, and actively sought unpublished data. We included RCTs
conducted in adults with knee OA comparing widely used pharma-
ceuticals (acetaminophen, non-selective NSAIDs, COX-2 selective
NSAIDs, topical NSAIDs, intra-articular (IA) corticosteroids, and IA
hyaluronic acid) against the following placebos: oral placebo, IA pla-
cebo, topical placebo and oralþtopical placebo. We calculated stand-
ardized mean differences (SMD) for pain at 12-week follow-up. We
performed network meta-analysis using a Bayesian random effects
model with non-informative priors. We also assessed the effect of
ignoring differential placebo responses on apparent treatment effects
by comparing our results with a network that assumes that all placebos
are the same (Figure 1).single placebo effect network.
Figure 3. Standardized mean differences of active treatments for pain at
12 weeks comparing results from deferential placebo effect network and
single placebo effect network
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an age range of 45 - 75 years. The proportion of women ranged
from 28% - 100%. For pain, IA placebo (SMD, 95% Credible Interval)
[0.28 (0.08, 0.48)] and topical placebo [0.20 (0.02, 0.38)] had sig-
niﬁcantly greater effects than oral placebo. The relative efﬁcacies and
the hierarchy of the active treatments were substantially changed by
ignoring the differential response to the placebo types (Figures 2 &
3). For example, in the differential placebo network model, IA and
topical therapies rank higher than oral, while in the non-differential
placebo network model, oral NSAIDs ranked higher.
Conclusions: Our results show that some types of placebo inter-
ventions are associated with greater responses. This supports the
notion that some placebo treatments can exert clinically relevant
effects. In other words, the method of treatment delivery might
have an important inﬂuence on outcome. These important differ-
ences also need to be accounted for in the design of future OA
studies.
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RANDOMIZED, DOUBLE-BLIND, MULTICENTER, NON INFERIORITY
CLINICAL TRIAL WITH COMBINED GLUCOSAMINE AND
CHONDROITIN SULFATE VS CELECOXIB FOR PAINFUL KNEE
OSTEOARTHRITIS
M.C. Hochberg y, J. Martel-Pelletier z, J. Monfort x, I. M€oller k,
P. du Souich{, J.-P. Pelletier z, MOVES Steering Committee. yDiv. of
Rheumatology & Clinical Immunology, Univ. of Maryland Sch. of Med.,
Baltimore, MD, USA; zOsteoarthritis Res. Unit Univ. of Montreal Hosp.
Res. Ctr. (CRCHUM), Montreal, QC, Canada; xRheumatology Dept., Hosp.
del Mar, Barcelona, Spain; k Inst. POAL de Reumatologia, Barcelona,
Spain; { Pharmacology Dept., Faculty of Med., Univ. of Montreal,
Montreal, QC, Canada
Purpose: The ﬁxed dose combination of glucosamine hydrochloride
and chondroitin sulfate (2 capsules GHclþCS; 250 mg and 200 mg,
respectively, three times daily) was found to be efﬁcacious compared to
placebo in subjects with knee osteoarthritis (OA) with severe pain in the
NIH-funded Glucosamine Arthritis Intervention Trial (GAIT) (N Engl J
Med 2006 Feb 23;354(8):795-808). The proportion of OA patients who
achieved the primary endpoint of a 20% improvement in pain was
similar between those randomized to GHclþCS and celecoxib 200 mg
daily in this 6-month symptom study. Subsequently, a phase IV
randomized controlled non-inferiority trial was designed to compare
the efﬁcacy of GHclþCS and celecoxib in patients with knee OA to
extend the ﬁndings from GAIT.
Methods: The Multicentric Osteoarthritis interVEntion Study with
Sysadoa (MOVES) was designed as a non-inferiority trial to compare the
efﬁcacy and safety of a ﬁxed dose combination of GHclþCS (Droglican,
Bioiberica SA, Barcelona, Spain) and celecoxib in patients with symp-
tomatic knee OA with severe pain. Patients were randomized in a
double-blind, double-dummy fashion to receive either 2 capsules of
Droglican (GHcl 250 mg and CS 200 mg) three times daily, or Celecoxib
200 mg capsule plus 5 placebo Droglican capsules per day. Patients
were eligible if they were aged 40 and above, fulﬁlled American College
of Rheumatology criteria for knee OA, had Kellgren-Lawrence (KL) grade2 or 3 radiographic severity and had a WOMAC pain scale of >301 units
(0-500 scale). Patients with high gastrointestinal or cardiovascular risk
were excluded. The primary outcome was the mean decrease in
WOMAC Pain subscale after 6 months of treatment; the non-inferiority
marginwas set at 40 (corresponding to 8 mm on a 0-100 mm scale) and
the sample size was calculated at 240 per group with 90% power. Mixed
model repeated measures was used to analyse the primary outcome;
time, treatment and time x treatment were included as ﬁxed effects.
Results: A total of 763 patients were screened and 606 randomized to
receive either Droglican (N¼304) or celecoxib (N¼302). Of these, 522
(86.1%) completed the 6-month trial and were included in the per-
protocol non-inferiority analysis; there was no difference in proportion
completing between groups. Mean (SD) age was 62.7 (8.9) years, 438
(83.9%) were women; KL grade 2 changes were present in 327 (62.6%).
The mean (SD) WOMAC pain score at randomization was 372.0 (41.8)
and 370.6 (41.4) in the Droglican and celecoxib groups, respectively.
The mean (SD) WOMAC pain score at 180 days was 185.8 (7.4) and
184.7 (7.6) in the Droglican and celecoxib groups, respectively, corre-
sponding to a mean (SEM) difference of 1.11 (10.63) units (95% con-
ﬁdence interval -21.99, 19.76) (P ¼ 0.917) that respects the non-
inferiority margin. These results were robust in sensitivity analyses
using the intention-to-treat population and when baseline observation
carried forward was used for imputation in both the per-protocol and
intent-to-treat populations. In addition, there was no signiﬁcant dif-
ference between the Droglican and celecoxib groups in the absolute
improvement in the WOMAC stiffness and function scales and the ﬁve
individual items of the WOMAC pain scale at 6 months. There was no
signiﬁcant difference in the proportion of patients with treatment-
emergent adverse events between the groups (50.7% overall); no
deaths occurred in this 6-month study.
Conclusions: These results demonstrated comparable efﬁcacy of a ﬁxed
dose combination of glucosamine hydrochloride and chondroitin sul-
phate (Droglican) to celecoxib for relief of severe knee pain in patients
with knee OA and a similar safety proﬁle. Further ongoing analyses will
examine key secondary endpoints including responder indices in this
population.
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STUDY OF THE EFFECT OF CHONDROITIN SULFATE ON PAIN IN KNEE
OSTEOARTHRITIS PATIENTS ASSESSED BY FUNCTIONAL MRI: A
RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED CLINICAL
TRIAL
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Purpose: The aim of the present fMRI study was to objectively identify
the effects of Chondroitin Sulfate (CS) treatment on the brain response
to pressure painful stimulation in patients with radiological and clinical
knee osteoarthritis.
Material and methods: The current study was developed in the
Rheumatology Department and the MRI Research Unit of the Hos-
pital del Mar in Barcelona, from December 2010 to January 2013. This
is a phase IV, randomized, double-blind clinical trial in which
patients received CS (Condrosan, Bioiberica S.A.) 800 mg/day or
placebo for a 4-month treatment course. 64 patients were random-
ized (32 to placebo and 32 to CS), and ﬁnally 51 patients were
evaluable by ITT (27 in the placebo group and 24 in the CS group).
Patients were assessed at baseline and post-treatment. Two tests
were conducted in each session by applying painful pressure on the
patella surface and on the knee medial interline, using a MRI-com-
patible algometer, during the acquisition of two 6-min fMRI
sequences. Stimulus intensity to be applied in both fMRI sessions was
individually adjusted prior to baseline fMRI. Each subject was asked
to rate the subjective pain perceived during the whole fMRI sequence
immediately after fMRI acquisition using NRS. All fMRI data were
processed using the Statistical Parametric Mapping (SPM8) package,
Wellcome Department of Imaging Neuroscience, running in Matlab
